Up To 150 Million Of Common Stock Authorized

Inspire Medical Systems Announces Share Repurchase Program

Up to $150 Million of Common Stock Authorized

Program to expire August 5, 2026

MINNEAPOLIS, Aug. 06, 2024 - Inspire Medical Systems, Inc. (NYSE: INSP) today announced that its Board of Directors has authorized the repurchase of up to $150 million of the company's outstanding common stock.

The share repurchase program will expire on August 5, 2026, subject to earlier termination or extension by the Board in its sole discretion.

"The Board's authorization of this share repurchase program reflects our confidence in Inspire's long-term growth prospects and our commitment to returning capital to our shareholders," said Tim Herbert, Inspire's President and Chief Executive Officer.

Purchases under the program may be made from time to time in the open market, in privately negotiated transactions, or through other means as determined by management. The timing and amount of any repurchases will depend on a variety of factors, including market conditions, the company's financial condition, and other investment opportunities.

About Inspire Medical Systems

Inspire Medical Systems, Inc. is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (OSA). The company's lead product, the Inspire Upper Airway Stimulation (UAS) therapy, is the first FDA-approved implantable treatment for OSA.

Inspire's mission is to improve the lives of patients with OSA by providing them with a safe, effective, and long-lasting solution to their condition. The company is headquartered in Minneapolis, Minnesota, and has operations in the United States, Europe, and Asia.